Find Funding Opportunities

Returning 144 results

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

PA
Monday, November 13, 2017
Tuesday, January 8, 2019
R21
PA-18-286

Funding Opportunity Purpose

The purpose of this FOA is to encourage submission of Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a new multidisciplinary approach to a biomedical challenge; 2) are high-risk but have high impact; and 3) develop data that may lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed)

PAR
Monday, November 13, 2017
Thursday, January 24, 2019
R25
PAR-18-346

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Insitute of Neurological Disorders and Stroke R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on research experiences, designed to foster the development of physicians as research scientists in areas relevant to the NINDS mission. The research experiences will prepare clinicians to successfully compete for individual NIH mentored career development awards, or where appropriate, independent research awards. This FOA will also support educational activities such that participants of the R25 are expected to attend and participate in an annual workshop specific to this FOA to present their work, discuss progress and plans towards transitioning to the next career stage and to network with other researchers and leaders in their fields. Such success will facilitate their transition from resident/fellow to physician-scientist, and will thus foster retention of a cadre of physician-scientists who will conduct research into the mechanisms of, etiology, and treatment of neurological diseases.

Translational Neural Devices (U44 - Clinical Trial Required)

RFA
Wednesday, November 8, 2017
Thursday, October 22, 2020
U44
RFA-NS-18-012

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

Translational Neural Devices (UG3/UH3 - Clinical Trial Required)

RFA
Wednesday, November 8, 2017
Thursday, October 22, 2020
UG3/UH3
RFA-NS-18-011

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design.

Altered neuronal circuits, receptors and networks in HIV-induced Central Nervous System (CNS) dysfunction (R01)-Clinical Trial Not Allowed

RFA
Tuesday, November 7, 2017
Tuesday, January 9, 2018
R01
RFA-MH-18-610

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Altered neuronal circuits, receptors and networks in HIV-induced Central Nervous System (CNS) dysfunction (R21- Clinical Trial Not Allowed)

RFA
Tuesday, November 7, 2017
Tuesday, January 9, 2018
R21
RFA-MH-18-611

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

PAR
Tuesday, November 7, 2017
Wednesday, May 8, 2019
R01
PAR-18-206

Funding Opportunity Purpose

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Bioengineering Research Partnerships (U01 Clinical Trial Optional)

PAR
Tuesday, November 7, 2017
Tuesday, January 8, 2019
U01
PAR-18-208

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.The goal of the program is to support projects that can realize meaningful solutions within 5 10 years.

BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)

RFA
Tuesday, November 7, 2017
Wednesday, April 8, 2020
F32
RFA-MH-18-510

Funding Opportunity Purpose

The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training.

Mechanisms, Models, Measurement, and Management in Pain Research (R01 Clinical Trial Optional)

PA
Tuesday, November 7, 2017
Wednesday, May 8, 2019
R01
PA-18-141

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Pages